Ocugen 배당 및 자사주 매입
배당 기준 점검 0/6
Ocugen 배당금을 지급한 기록이 없습니다.
핵심 정보
n/a
배당 수익률
-16.6%
자사주 매입 수익률
| 총 주주 수익률 | -16.6% |
| 미래 배당 수익률 | n/a |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | n/a |
최근 배당 및 자사주 매입 업데이트
업데이트 없음
Recent updates
Seeking Alpha • 19h
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
Summary Ocugen, Inc. is maintained at a Hold rating due to mixed clinical progress and ongoing pivotal trials across its ophthalmology pipeline. The company's OCU400 gene-agnostic therapy for retinitis pigmentosa shows promise, with phase 3 liMeliGhT top-line data expected in Q1 2027 and strong phase 1/2 results. OCU410ST for Stargardt disease faces uncertainty after a negative interim analysis, but the phase 2/3 GARDian3 trial will continue with full sample assessment. OCGN's cash runway extends into 2028 following a $130M convertible note raise, reducing near-term dilution risk and supporting ongoing R&D. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 16
OCGN: Upcoming Gene Therapy Readouts And RMAT Status May Re Rate Shares
Analysts lifted their Ocugen fair value estimate from $7.00 to $8.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin, and a very large future P/E multiple that reflects the company’s clinical pipeline and upcoming trial milestones. Analyst Commentary Street research coverage on Ocugen remains active, with recent updates giving investors a mix of optimism around the clinical pipeline and a reminder of the risks that come with early stage biotech exposure.내러티브 업데이트 • Aug 02
OCGN: Upcoming Gene Therapy Trials And RMAT Pathway Could Re Rate Shares
Ocugen's updated analyst price target has shifted modestly to $11 from $12, with analysts pointing to recent discussions on upcoming clinical milestones and trial preparations as the key reasons for refining their models. Analyst Commentary Recent commentary on Ocugen highlights a mix of interest in the clinical pipeline and caution around how that pipeline translates into long term value.
내러티브 업데이트 • Jul 07
OCGN: Upcoming Retinal Trial Readouts Will Shape Future Upside Potential
Analysts raised their fair value estimate for Ocugen to about $20.62 from $15.00, citing updated assumptions for revenue potential, profitability, and a lower expected future P/E multiple based on recent clinical and regulatory progress discussed in recent research. Analyst Commentary Recent Street research on Ocugen shows a mix of optimism around the pipeline and caution around timing and execution, which together help explain the latest fair value revisions.
내러티브 업데이트 • Jun 23
OCGN: Gene Therapy Pivotal Trials And 2027 Readouts Will Drive Repricing
Ocugen's analyst price target has shifted modestly, with one firm trimming its view from $12 to $11 while others recently raised their targets by $3 to $4. This reflects analysts' focus on the company's gene therapy pipeline, ongoing pivotal trials and upcoming clinical catalysts.내러티브 업데이트 • Jun 05
OCGN: Retinal Gene Therapies Will Gain Momentum With Upcoming 2027 Readouts
Ocugen's analyst price target has edged down by $0.14 to $11.43 as analysts refresh their models around updated expectations for revenue growth, profitability, and long term P/E assumptions following recent gene therapy trial updates and upcoming catalysts across the retinal disease pipeline. Analyst Commentary Recent research updates show a mix of optimism around Ocugen's gene therapy pipeline and some caution on execution risk and timing, which is feeding into the modest reset in the average price target.내러티브 업데이트 • Apr 26
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.내러티브 업데이트 • Apr 11
OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.내러티브 업데이트 • Mar 28
OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.내러티브 업데이트 • Mar 12
OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.내러티브 업데이트 • Feb 25
OCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.내러티브 업데이트 • Feb 11
OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.내러티브 업데이트 • Jan 27
OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.내러티브 업데이트 • Jan 12
OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.내러티브 업데이트 • Dec 15
OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.내러티브 업데이트 • Nov 29
OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.내러티브 업데이트 • Nov 15
OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.내러티브 업데이트 • Nov 01
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.내러티브 업데이트 • Oct 17
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.내러티브 업데이트 • Oct 03
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
새로운 내러티브 • Apr 02
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 OCGN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: OCGN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| Ocugen 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (OCGN) | n/a |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.1% |
| 업계 평균 (Biotechs) | 2.1% |
| 분석가 예측 (OCGN) (최대 3년) | n/a |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 OCGN 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 OCGN 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 OCGN 의 지급 비율을 계산하기에는 데이터가 부족합니다.
주주 현금 배당
현금 흐름 범위: OCGN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/11 12:03 |
| 종가 | 2026/09/10 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Ocugen, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Elemer Piros | Lucid Capital Markets |